Blog
RSS FeedPosted by Michael Wonder on 21 Jan 2025
Anti-PD-L1 tagitanlimab approved for marketing by the National Medical Products Administration
20 January 2025 - The board of directors of Sichuan Kelun-Biotech Biopharmaceutical is pleased to announce that the Company received ...
Posted by Michael Wonder on 21 Jan 2025
Albertan with rare blood cancer calls on Health Canada to approve life-saving drug
20 January 2025 - An Alberta woman living with a rare form of blood cancer is calling on Health Canada ...
Posted by Michael Wonder on 21 Jan 2025
Takeda's Fruzaqla (fruquintinib) receives Health Canada market authorisation for metastatic colorectal cancer
20 January 2025 - Positive reimbursement recommendations by Canada's Drug Agency and Institut National d'excellence en Santé et Services Sociaux. ...
Posted by Michael Wonder on 21 Jan 2025
Immunotherapy Qarziba to be reimbursed for high-risk neuroblastoma patients starting next month
28 November 2024 - The treatment landscape for neuroblastoma, the most common cancer in children outside of blood and brain ...
Posted by Michael Wonder on 20 Jan 2025
European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer
20 January 2025 - Expanded approval includes MMRp/MSS tumours, which represent approximately 75% of endometrial cancer cases. ...
Posted by Michael Wonder on 20 Jan 2025
Handok's AML treatment Vyxeos receives insurance coverage in Korea
2 December 2024 - Handok said Monday that its acute myeloid leukaemia treatment, Vyxeos liposomal injection (cytosine arabinoside and daunorubicin ...
Posted by Michael Wonder on 19 Jan 2025
Junshi Biosciences announces toripalimab’s approval in Australia
17 January 2025 - Shanghai Junshi Biosciences announced that toripalimab, the anti-PD-1 monoclonal antibody self-developed by the company, has obtained the ...
Posted by Michael Wonder on 19 Jan 2025
Long wait for cancer drug approvals causing 'great anguish' among patients, doctors
18 January 2025 - Potentially life-saving treatments delayed by bureaucracy, doctors say. ...
Posted by Michael Wonder on 19 Jan 2025
US FDA approves FoundationOne CDx as a companion diagnostic for Ojemda (tovorafenib) to treat the most common form of childhood brain tumour in paediatric patients
17 January 2025 - The approval supports the identification of therapeutic options for patients with relapsed or refractory BRAF altered paediatric ...
Posted by Michael Wonder on 17 Jan 2025
Senaparib approved by NMPA for first-line maintenance therapy in ovarian cancer
16 January 2025 - Impact Therapeutics is pleased to announce that senaparib capsules has received marketing authorisation in China from ...
Posted by Michael Wonder on 17 Jan 2025
FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR positive, HER2 negative breast cancer
17 January 2025 - Today, the FDA approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo), a Trop-2-directed antibody and topoisomerase inhibitor conjugate, ...
Posted by Michael Wonder on 17 Jan 2025
Rybrevant plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR mutated advanced lung cancer
16 January 2025 - Phase 3 MARIPOSA-2 study showed Rybrevant in combination with carboplatin and pemetrexed significantly improved progression-free survival compared ...
Posted by Michael Wonder on 17 Jan 2025
Innovent receives NMPA breakthrough therapy designation for IBI343 (anti-CLDN18.2 ADC) as monotherapy for advanced pancreatic cancer
16 January 2025 - Innovent Biologics announced that the Center for Drug Evaluation of China's National Medical Products Administration has granted ...
Posted by Michael Wonder on 16 Jan 2025
FDA approves sotorasib with panitumumab for KRAS G12C mutated colorectal cancer
16 January 2025 - Today, the FDA approved sotorasib (Lumakras, Amgen) with panitumumab (Vectibix, Amgen) for adult patients with KRAS ...
Posted by Michael Wonder on 16 Jan 2025
Foresee Pharmaceuticals announces the PDUFA goal date for the 3 month version of Camcevi is 29 August 2025
13 January 2025 - Foresee Pharmaceuticals announces that the US FDA issued a Day 74 letter. ...